Puente-Moncada et al. [112] evaluated differences in proliferation, apoptosis and glucose metabolism between AML cell lines with (MV-4-11 and MOLM-13) and without FLT3-ITD mutations (OCI-AML3 and U-937) after melatonin treatment. The gene discussed is FLT3; the disease is acute myeloid leukemia.